Offering Announcement
Nuvectis Pharma Inc (NASDAQ:NVCT), a clinical‑stage biopharmaceutical company focused on immune complement‑related conditions and oncology, announced the commencement of an underwritten public offering of its common stock. All shares to be sold are being offered by Nuvectis itself, and Cantor is acting as the sole book‑runner for the transaction. The offering is subject to market and other conditions, and the company provides no assurance regarding the completion, size, or terms of the offering.
Market Reaction
In after‑hours trading on Monday, Nuvectis Pharma shares declined 20.5%, reflecting investor response to the offering announcement.
Underwriter Option
The company disclosed that underwriters have a 30‑day option to purchase up to an additional 15% of the shares offered in the transaction.
Use of Proceeds
Nuvectis stated that net proceeds will be allocated to advance its development programs for pipeline candidates NXP100, NXP200 and NXP900, as well as any future product candidates. Additional uses include hiring additional personnel, capital expenditures, costs associated with operating as a public company, and other general corporate purposes.
Pipeline Overview
The pipeline comprises NXP100, a complement Factor B inhibitor under development for complement‑mediated diseases, and oncology candidates NXP200 and NXP900 targeting advanced cancers.